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Three major strategies, that are not mutually exclusive, are being developed to tackle the problem of respiratory distress syndrome in preterm infants. The first is to prevent premature birth itself through improved obstetrical follow up and care; however, this has proved not to be an easy task.' The second is to optimise the postnatal treatment of infants with respiratory distress through the availability of neonatal intensive care units and their motorised or airborne transportation teams, as well as through the use of novel medication and techniques, for example, the endotracheal administration of biosynthetic pulmonary surfactant, artificial ventilation with liquid or high frequency oscillation, and extracorporal membrane oxygenation. The third strategy is to administer, in cases of threatening premature birth, a treatment to the fetus that accelerates the fetal preparation for neonatal respiration, thus preventing the development of neonatal respiratory distress.
The concept of accelerating fetal maturation was launched in 1969, when Liggins noted as an epiphenomenon of his study on the initiation of parturition in the ewe that the infusion of dexamethasone had a stimulatory effect on the lung aeration of prematurely delivered lambs.2 This pioneering observation has now been repeatedly confirmed and has been extended to numerous miammalian species, including the human. In addition, the underlying pathophysiological mechanisms are increasingly well understood. 3 The principle has been applied successfully in human perinatal medicine, where the administration of glucocorticoids to the pregnant woman-and thus transplacentally to the fetus-has served as the 'gold standard' of fetal maturational treatment for nearly two decades.4 5 The regulation of lung development during fetal life has been documented extensively to be under multihormonal control. [19] [20] [21] [22] TRH is subject to rapid enzymatic breakdown in tissues (including the anterior pituitary), serum and other body fluids, yielding several metabolites of uncertain physiological signifi-Prenatal treatment with thyrotrophin releasing hormone to prevent neonatal respiratory distress cance.'°In the human adult, the pharmacokinetics of TRH are partly regulated by the thyroid status; in euthyroid conditions, the plasma halflife ofTRH is almost seven minutes. 23 In pregnant women, the serum TRH degrading activity is lower than in euthyroid, non-pregnant adults. 24 Intravenously infused TRH appears to be distributed exclusively in the extracellular fluid. 23 The permeability of the blood-brain barrier to TRH is poor.25 TRH, in contrast to thyroxine and TSH, crosses the human placenta readily.6 26 The pharmacokinetics of TRH in the human fetus and newborn have not yet been reported. Raised plasma TRH concentrations, largely from extrahypothalamic origin, have been documented in the fetal rat and sheep at midgestation.'9 20 The cord serum TRH concentration of the human infant at term birth is raised and falls within the days after birth. 20 The TRH degrading activities in human fetal serum and in human neonatal cerebrospinal fluid are very low compared with adult standards.24 27 The TRH receptors localised in the pituitary, in the gastrointestinal tract, and in the nervous system resemble each other.28 29 Although the latter are ubiquitously distributed, the highest densities are found in limbic structures, particularly the hypothalamus and the amygdala, in the brain stem, the cerebellum, and the grey matter of the spinal cord; lower densities are present in the dorsal roots and ganglia of the spinal cord. 30 36 3 The human fetal TSH reponse to maternal administration of TRH was recently evaluated in utero between 25 and 37 weeks' gestation; this study demonstrated a striking fetal TSH response of up to 100 mU/l within 10-30 minutes from the intravenous TRH injection.38 It is noteworthy that the TSH response of the third trimester human fetus to exogenous TRH is at least in the range of the TSH surge normally observed within the first hours after birth and presumably elicited by endogenous TRH of hypothalamic origin. 39 40 In the human, maternal intravenous administration of TRH does not appear to influence fetal prolactin secretion. 37 The fetal thyroid gland becomes increasingly responsive to endogenous TSH stimulation throughout the third trimester of pregnancy, as evidenced by gradually rising serum thyroxine concentrations in the face of relatively constant serum TSH concentrations.4142 Therefore, the TRH evoked TSH response is considered to be the principal mediator of the changes in fetal thyroid status that occur after. exposure to exogenous TRH. In the term human fetus, these changes include a significant rise in serum thyroxine concentrations within 60 minutes,26 37 as well as a doubling of the circulating triiodothyronine concentrations within 120 minutes from intravenous maternal TRH injection.36 The increase of serum thyroxine is exclusively of fetal thyroidal origin, whereas the augmented concentrations of bioactive triiodothyronine are largely derived from thyroxine deiodination in fetal peripheral tissues.20 This deiodination activity has been correlated with the fetal serum concentration of endogenous cortisol and can be further stimulated by exogenous glucocorticoids.20 43 The TRH induced serum concentrations of thyroxine and tri-iodothyronine return to baseline concentrations within a few hours. 26 31 36 Thyrotrophin releasing hormone It has been conclusively demonstrated that tri-iodothyronine accelerates the synthesis of surfactant in the fetal lung, particularly the synthesis of the phosphatidylcholine fraction. Moreover, tri-iodothyronine has a potent additive effect on the capacity of glucocorticoids to enhance surfactant synthesis. The actions of both hormones on the type II alveolar cells are mediated by different receptors and proceed through different biochemical mechanisms (reviewed by Ballard'). ( 
2) PULMONARY FLUID AND ION TRANSPORT
The fetal lung is filled with a chloride rich fluid that is actively secreted by the pulmonary epithelium towards the pharynx, where it is either swallowed or propulsed outside the oral cavity, thus contributing to the amniotic fluid (reviewed by Strang45). The intrapulmonary pressure exerted by lung fluid and modulated by the laryngeal sphincter seems to be an important stimulator of fetal lung growth." 6 47 Normally, fluid production is diminished and reabsorption augmented in the immediate perinatal period. This is the result of the combined decreases in alveolar tension and in lymphatic and capillary hydrostatic pressure, of the increases in transpulmonary pressure and in plasma colloid pressure, and-most importantly-of the activated sodium transport by alveolar epithelial cells. These forces promote movement of sodium ions and water from the alveolar space through the apical membrane of epithelial cells into the lung interstitium, and finally into the lymphatic and systemic circulation. Insufficient or delayed clearance of lung fluid at birth leads to the clinical picture of 'transient neonatal tachypnoea', the most frequent cause of respiratory distress in infants born at term. Current evidence indicates that the principal mediators of the perinatal shift in lung fluid and ion transport are the catecholamines, atrial natriuretic peptide, and possibly vasopressin. Thyroid hormones and glucocorticoids appear to play a pivotal part as their increasing serum concentrations during development are required to sensitise the fluid flux to catecholamines." Atrial natriuretic peptide has been shown to decrease fetal lung fluid production possibly through endocrine and pulmonary paracrine pathways. 49 50 The demonstration that tri-iodothyronine and glucocorticoids increase the synthesis of atrial natriuretic factor by the alveolar type II cells suggests a stimulating effect of both hormones on this aspect of fetal lung maturation.50 (3) THE CARDIOVASCULAR SYSTEM At birth, the respiratory organ of the fetus, the placenta, is replaced by the lungs as the site of gas exchange. Moreover, metabolic and thermoregulatory activities increase, leading to a substantial rise in oxygen consumption. These respiratory adaptations are largely mediated by circulatory changes.
The switch in respiratory organ involves the constriction of the ductus arteriosus and a dramatic fall in pulmonary vascular resistance. Both these phenomena appear to be essentially the result of shifts in arachidonic acid metabolism involving lipoxygenase products (leukotrienes) and cyclo-oxygenase products (prostaglandins and thromboxane).5' Thyroid hormones facilitate the postnatal closure of the ductus arteriosus, as suggested by the raised incidence of patent ductus arteriosus in infants with congenital hypothyroidism.52 Glucocorticoids are also known to have a maturational effect on the ductus arteriosus, by decreasing the ductus' sensitivity to the relaxing action of prostaglandin E2. 53 The fulfilment of the neonatal rise in oxygen demand is partly accomplished through a marked increase in cardiac output, which is in turn mainly mediated by augmented concentrations of circulating catecholamines acting on myocardial I6 adrenergic receptors. To obtain the necessary ,1 adrenergic receptor availability, the presence of thyroid hormones appears to be crucial.5" Interestingly, the prenatal circulating thyroid hormone concentrations are more important than the postnatal concentrations for this vital adaptive function.55 A recent cardiotocographic study of the preterm human fetus has shown that the maternal administration of TRH increases within an hour the frequency of fetal heart rate accelerations and increases the fetal heart rate variability; increases in these two variables are currently considered as indicators of improved fetal well being (W Gyselaers et al, unpublished observations). Intermittently, the fetus makes rapid and irregular breathing movements that are of a magnitude comparable with postnatal respiration. These breathing movements participate in the circulation of lung fluid within the respiratory tract and provoke periodic oscillati6ns in the pulmonary transmural pressure, both of which contribute to normal growth of the fetal lungs.56
The breathing activity in utero is also important for adequate development of the diaphragm and the intercostal muscles.56 The fetal efforts of these respiratory muscles have a profound effect on the configuration of the neonatal chest wall and the condition of these muscles at birth largely determines the infant's potential for efficient ventilation, particularly when the infant is born prematurely.57
In the fetal lamb, the intravenous or intracerebroventricular administration of TRH elicits-apparently through non-endocrine pathways-a behavioural arousal with increased body and eye movements and provokes a marked stimulation of fetal breathing movements, which become continuous, faster, and deeper.58 59 These data have even led to the suggestion that the presumed surge in TRH secretion at birth plays a part in the switch from a fetal to a postnatal breathing pattern. 58 The effect of TRH on breathing activity in the human fetus has not been reported. How-ever, the cardiotocograpblic study of the human fetus after administration of TRH to the pregnant woman provides indirect evidence for an effect of TRH on human fetal behaviour and breathing comparable with the effect observed in the fetal lamb (W Gyselaers et al, unpublished observations). Indeed, the reported increase in the frequency of fetal heart rate accelerations suggests an increase in fetal body movements, as 91-98% of fetal heart rate accelerations are normally associated with fetal body movements."0 61 Similarly, the reported increase in fetal heart rate variability is suggestive of an increase in fetal breathing movements, as there is also a close and positive correlation between these two variables.' 
